<DOC>
	<DOCNO>NCT01789255</DOCNO>
	<brief_summary>This pilot phase II trial study well give vorinostat , tacrolimus , methotrexate work prevent graft-versus-host disease ( GVHD ) stem cell transplant patient hematological malignancy . Vorinostat , tacrolimus , methotrexate may effective treatment GVHD cause bone marrow transplant .</brief_summary>
	<brief_title>Vorinostat , Tacrolimus , Methotrexate Preventing GVHD After Stem Cell Transplant Patients With Hematological Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety feasibility addition vorinostat tacrolimus methotrexate GVHD prophylaxis . SECONDARY OBJECTIVES : I . To determine day 100 grade 2-4 acute GVHD . II . To determine 1-year overall survival relapse-free survival . III . To correlate plasma concentration inflammatory marker acute GVHD . IV . To correlate protein acetylation peripheral blood mononuclear cell administration vorinostat . OUTLINE : Patients receive vorinostat orally ( PO ) twice daily ( BID ) day -10 100 . Beginning day -3 , patient receive tacrolimus intravenously ( IV ) continuously PO BID ( cyclosporine IV continuously PO patient unable tolerate tacrolimus ) taper day 100-180.Patients also receive methotrexate IV daily ( QD ) day 1 , 3 , 6 , 11 . After completion study treatment , patient follow periodically 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<criteria>A prospective patient allogeneic HSCT hematologic condition , malignant nonmalignant ; donor unrelated marrow peripheral blood cell ; patient history central nervous system ( CNS ) involvement eligible CNS disease remission time study consideration The donor recipient must human leukocyte antigen ( HLA ) 8/8 allelic match HLAA , B , C , DRB1 ; highresolution typing require allele Diagnoses include : Acute myelogenous leukemia follow stage : First remission Second subsequent remission Complete remission define absence blast peripheral circulation time enrollment &lt; 5 % blast bone marrow Chronic myelogenous leukemia follow stage : First subsequent chronic phase : Patient refuse tyrosine kinase therapy otherwise suit Stable , hematologic remission : blast present marrow and/or peripheral blood , disease qualify accelerate blast phase Hematologic remission : blast cell precursor cell blood marrow Partial cytogenetic remission : Philadelphia chromosome positive ( Ph+ ) metaphases &gt; 0 % &lt; 35 % Complete cytogenetic remission : absence Ph+ metaphase Accelerated phase one follow symptom : White blood cell ( WBC ) difficult control ( &gt; 50 x 10^9/L despite therapy ) Rapid double WBC ( &lt; 5 day ) 10 % blast blood marrow 20 % blast and/or promyelocytes blood marrow 20 % basophil and/or eosinophil blood Anemia thrombocytopenia unresponsive standard treatment Persistent thrombocytosis ( &gt; 1000 x 10^9/L ) Cytogenetic abnormality addition Ph+ Increasing splenomegaly Marrow fibrosis Myelodysplastic syndrome follow stage : Refractory anemia Refractory anemia ring sideroblast Refractory cytopenia multilineage dysplasia Refractory cytopenia multilineage dysplasia ring sideroblast Refractory anemia excess blasts1 ( 510 % blast ) Refractory anemia excess blasts2 ( 1020 % blast ) Myelodysplastic syndrome , unclassified Myelodysplastic syndrome ( MDS ) associate isolated del ( 5q ) Chronic myelomonocytic leukemia Primary Myelofibrosis Intermediate2 risk high risk disease Patients extinguish standard care option prior consider trial Chronic lymphocytic leukemia Complete remission : disease completely absent relapse occur prior preparative regimen ; require follow : Nodular partial remission : complete response persistent lymphoid nodules bone marrow Partial remission : reduction 50 % disease burden regardless number line therapy receive Mature B cell malignancy Patients extinguish standard care option prior consider eligible trial First complete remission ( CR1 ) confirm : complete disappearance know disease ; term `` confirm '' define laboratory and/or pathological radiographic determination . CR1 unconfirmed ( CRU1 ) : complete disappearance know disease exception persistent scan abnormality unknown significance ; term `` unconfirmed '' define scan abnormality unknown significance biopsied otherwise evaluate Second subsequent complete remission ( CR2+ ) confirm : recipient relapse , achieve complete absence disease without radiographic evidence disease CR2+ unconfirmed : recipient achieve second subsequent complete response persistent radiographic abnormality unknown significance . Partial remission : reduction &gt; = 50 % great diameter site know disease new site Karnofsky &gt; = 70 % Life expectancy great 6 month Total bilirubin = &lt; 2.5 mg % ( unless Gilbert 's disease diseaserelated ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) &lt; 3.0 X institutional upper limit normal Estimated actual glomerular filtration rate ( GFR ) &gt; 50 mL/min/1.73 m^2 patient creatinine level institutional normal ; GFR correct body surface area ( BSA ) Diffusing capacity lung carbon monoxide ( DLCO ) &gt; 50 % ; DLCO correct hemoglobin Forced expiratory volume 1 second ( FEV1 ) &gt; 50 % Forced vital capacity ( FVC ) &gt; 50 % Ejection fraction &gt; = 50 % The effect vorinostat develop human fetus unknown ; reason histone deacetylase inhibitor agent well therapeutic agent use trial ( e.g. , tacrolimus methotrexate ) know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation ; woman become pregnant suspect pregnant partner participate study , inform treat physician immediately ; men treat enrolled protocol must also agree use adequate contraception prior study , duration study participation , 4 month completion vorinostat administration Ability understand willingness sign write informed consent document Patients must able swallow capsules/tablets Patients candidate unrelated donor allogeneic HSCT base current institutional bone marrow transplant ( BMT ) program clinical practice guideline ; organ function criterion utilized per current institutional BMT program clinical practice guideline ; restriction study entry base hematological parameter History allergic reaction attribute compound similar chemical biologic composition vorinostat Patients undergoing total body irradiation ( TBI ) base condition regimen ( TBI 1200 centigray [ cGy ] ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ; patient still therapy presumed proven infection eligible provide clear evidence ( radiographic finding and/or culture result ) infection wellcontrolled ; patient treatment infection enrol clearance Principal Investigator ( PI ) Pregnant woman exclude study vorinostat histone deacetylase inhibitor agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother vorinostat , breastfeed discontinue mother treated vorinostat Patients evidence human immunodeficiency virus ( HIV ) seropositivity and/or positive polymerase chain reaction ( PCR ) assay , human Tlymphotropic virus ( HTLV ) 1/HTLV2 seropositivity ; safety allogeneic HSCT yet wellestablished population Patients evidence hepatitis B hepatitis C PCR positivity ; hepatitis reactivation follow myelosuppressive therapy lead fatal complication Patients history prolong correct QT interval ( QTc ) syndrome Patients ask prior treatment drug like vorinostat ( i.e. , valproic acid ) within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>